NFA
BCRX icon

Nationwide Fund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nationwide Fund Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-43,926
Closed -$230K – 238
2017
Q3 		$230K Sell
43,926
-2,223
-5% -$11.4K ﹤0.01% 2571
2017
Q2 		$257K Buy
46,149
+1,975
+4% +$12K ﹤0.01% 2523
2017
Q1 		$371K Sell
44,174
-1,739
-4% -$12.1K ﹤0.01% 2312
2016
Q4 		$291K Sell
45,913
-2,700
-6% -$14K ﹤0.01% 2444
2016
Q3 		$214K Hold
48,613
– – ﹤0.01% 2591
2016
Q2 		$138K Sell
48,613
-35,856
-42% -$111K ﹤0.01% 2784
2016
Q1 		$238K Sell
84,469
-45,679
-35% -$202K ﹤0.01% 2453
2015
Q4 		$1.34M Sell
130,148
-105
-0.1% -$1.04K 0.01% 1567
2015
Q3 		$1.49M Buy
130,253
+51,317
+65% +$685K 0.01% 1526
2015
Q2 		$1.18M Sell
78,936
-10,524
-12% -$120K ﹤0.01% 1762
2015
Q1 		$808K Buy
89,460
+23,783
+36% +$246K ﹤0.01% 1996
2014
Q4 		$799K Buy
65,677
+11,878
+22% +$131K ﹤0.01% 1924
2014
Q3 		$526K Sell
53,799
-206
-0.4% -$2.52K ﹤0.01% 2179
2014
Q2 		$689K Buy
+54,005
New +$525K ﹤0.01% 2079
2013
Q3 		– Sell
-22,090
Closed -$34K – 3262
2013
Q2 		$34K Buy
+22,090
New +$38.1K ﹤0.01% 3029

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Nationwide Fund Advisors's BCRX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2017, closing a stake of 43,926 shares — an estimated $230K sold.

Nationwide Fund Advisors first reported a position in BCRX in Q2 2013 and held it in 15 quarters. The position peaked at $1.49M in Q3 2015. 116 funds tracked by Wall St. Rank hold BCRX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 43,926 BioCryst Pharmaceuticals shares in Q4 2017, an estimated $230K.
  • Nationwide Fund Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Nationwide Fund Advisors's BioCryst Pharmaceuticals position peaked at $1.49M in Q3 2015.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.